Gabriel Moraes Kuniyoshi

Gabriel Moraes Kuniyoshi

Auto-generated profile, based on publicly available information

Gabriel Moraes Kuniyoshi


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
GKGabriel Moraes Kuniyoshi
Gabriel Moraes Kuniyoshi
RCRafael Zoppi Campane
Rafael Zoppi Campane
NPNikita Patil
Nikita Patil
AOAna Vitorino de Oliveira
Ana Vitorino de Oliveira
BABeatriz Araújo
Beatriz Araújo
RKRicardo Ryoshi Kuniyoshi
Ricardo Ryoshi Kuniyoshi
Background: Percutaneous left atrial appendage occlusion (LAAO), alternative to oral anticoagulation (OAC), currently faces non-standardized bleeding data and imprecise borderline ischemic signals within the direct oral anticoagulant (DOAC) era. Objective: This study applied a pragmatic framework to evaluate the comparative efficacy and safety of LAAO versus OAC in a DOAC-predominant setting. Methods: PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing LAAO with OAC, restricted to a DOAC-predominant comparator. Risk ratios (RR) with 95% confidence intervals (CI) were calculated via a Mantel-Haenszel random-effects model. Results: Four trials comprising 5,890 patients were included (96.4% of controls assigned to DOACs). Overall stroke (RR 1.18, 95% CI 0.87–1.60; p=0.28), systemic embolism (RR 1.09, 95% CI 0.29–4.07; p=0.89), major bleeding (RR 0.98, 95% CI 0.81–1.19; p=0.84), hemorrhagic stroke (RR 0.82, 95% CI 0.45–1.51; p=0.53), and all-cause mortality (RR 1.00, 95% CI 0.85–1.17; p=0.98) did not differ significantly. Ischemic stroke presented a persistent numerical asymmetry favoring OAC that approached statistical significance (RR 1.36, 95% CI 0.99–1.89; p=0.06). Conversely, within available protocol-defined datasets, LAAO significantly reduced nonprocedural clinically relevant bleeding (RR 0.50, 95% CI 0.42–0.59; p<0.01). Conclusions: In a pragmatic analysis of the DOAC era, randomized data show statistical equivalence for individual hard clinical endpoints, alongside a persistent numerical asymmetry for ischemic stroke. The reduction in nonprocedural clinically relevant bleeding is driven by the attenuation of late non-major events. Current evidence remains non-definitive, warranting shared clinical decision-making to balance individual thromboembolic risks against long-term bleeding susceptibility.